Alto Neuroscience (NYSE:ANRO) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Alto Neuroscience (NYSE:ANRO) posted its quarterly earnings data on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.13, FiscalAI reports.

Alto Neuroscience Trading Down 1.9%

NYSE ANRO opened at $30.57 on Thursday. Alto Neuroscience has a 12 month low of $10.80 and a 12 month high of $37.48. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average of $26.63 and a 200-day moving average of $24.50. The company has a market cap of $1.20 billion, a PE ratio of -12.54 and a beta of 1.42.

Analyst Ratings Changes

ANRO has been the subject of several recent research reports. HC Wainwright increased their target price on shares of Alto Neuroscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Wedbush lifted their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. BTIG Research reissued a “buy” rating and set a $37.00 price target on shares of Alto Neuroscience in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Tuesday, October 27th. Finally, Wall Street Zen cut Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $37.88.

Insiders Place Their Bets

In other Alto Neuroscience news, CFO Nicholas Smith sold 110,830 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $26.58, for a total transaction of $2,945,861.40. Following the sale, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $639,514.80. This represents a 82.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 11.25% of the company’s stock.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.